Brain cancer research has been hampered by a paucity of viable clinical tissue of sufficient quality and quantity for experimental research. This has driven researchers to rely heavily on long term cultured cells which no longer represent the cancers from which they were derived. Resection of brain tumors, particularly at the interface between normal and tumorigenic tissue, can be carried out using an ultrasonic surgical aspirator (CUSA) that deposits liquid (blood and irrigation fluid) and resected tissue into a sterile bottle for disposal. To determine the utility of CUSA-derived glioma tissue for experimental research, we collected 48 CUSA specimen bottles from glioma patients and analyzed both the solid tissue fragments and dissociated tumor cells suspended in the liquid waste fraction. We investigated if these fractions would be useful for analyzing tumor heterogeneity, using IHC and multi-parameter flow cytometry; we also assessed culture generation and orthotopic xenograft potential. Both cell sources proved to be an abundant, highly viable source of live tumor cells for cytometric analysis, animal studies and in-vitro studies. Our findings demonstrate that CUSA tissue represents an abundant viable source to conduct experimental research and to carry out diagnostic analyses by flow cytometry or other molecular diagnostic procedures.
Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996, doi:10.1056/NEJMoa043330.
[3]
Finley, J.L.; Silverman, J.F.; Dickens, M.A. Immunocytochemical evaluation of central nervous system tumors obtained by the Cavitron ultrasonic surgical aspirator. Diagn. Cytopathol. 1990, 6, 308–312.
[4]
Gomez, G.G.; Kruse, C.A. Isolation and culture of human brain tumor cells. Methods Mol. Med. 2004, 88, 101–109.
[5]
Beckner, M.E.; Jane, E.P.; Jankowitz, B.; Agostino, N.R.; Walter, K.A.; Hamilton, R.L.; Pollack, I.F. Tumor cells from ultrasonic aspirations of glioblastomas migrate and form spheres with radial outgrowth. Cancer Lett. 2007, 255, 135–144, doi:10.1016/j.canlet.2007.04.005.
[6]
Oakes, W.J.; Friedman, H.S.; Bigner, S.H.; Bullock, N.H.; Bigner, D.D. Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note. J. Neurosurg. 1990, 72, 821–823, doi:10.3171/jns.1990.72.5.0821.
Snuderl, M.; Fazlollahi, L.; Le, L.P.; Nitta, M.; Zhelyazkova, B.H.; Davidson, C.J.; Akhavanfard, S.; Cahill, D.P.; Aldape, K.D.; Betensky, R.A.; et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20, 810–817, doi:10.1016/j.ccr.2011.11.005.
[9]
Szerlip, N.J.; Pedraza, A.; Chakravarty, D.; Azim, M.; McGuire, J.; Fang, Y.; Ozawa, T.; Holland, E.C.; Huse, J.T.; Jhanwar, S.; et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA 2012, 109, 3041–3046, doi:10.1073/pnas.1114033109.
[10]
Little, S.E.; Popov, S.; Jury, A.; Bax, D.A.; Doey, L.; Al-Sarraj, S.; Jurgensmeier, J.M.; Jones, C. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res. 2012, 72, 1614–1620, doi:10.1158/0008-5472.CAN-11-4069.
[11]
Pollard, S.M.; Yoshikawa, K.; Clarke, I.D.; Danovi, D.; Stricker, S.; Russell, R.; Bayani, J.; Head, R.; Lee, M.; Bernstein, M.; et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4, 568–580, doi:10.1016/j.stem.2009.03.014.
[12]
Wykosky, J.; Gibo, D.M.; Stanton, C.; Debinski, W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 2005, 3, 541–551, doi:10.1158/1541-7786.MCR-05-0056.
[13]
Binda, E.; Visioli, A.; Giani, F.; Lamorte, G.; Copetti, M.; Pitter, K.L.; Huse, J.T.; Cajola, L.; Zanetti, N.; Dimeco, F.; et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 2012, 22, 765–780, doi:10.1016/j.ccr.2012.11.005.
[14]
Day, B.W.; Stringer, B.W.; Al-Ejeh, F.; Ting, M.T.; Wilson, J.; Ensbey, K.S.; Jamieson, P.R.; Bruce, Z.C.; Lim, Y.C.; Offenhauser, C.; et al. EphA3 Maintains Tumorigenicity and is a Therapeutic Target in Glioblastoma Multiforme. Cancer Cell 2013, 23, 238–248, doi:10.1016/j.ccr.2013.01.007.
[15]
Hermanson, M.; Funa, K.; Hartman, M.; Claesson-Welsh, L.; Heldin, C.H.; Westermark, B.; Nister, M. Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992, 52, 3213–3219.
